Sun-Ranbaxy deal gets final CCI nod; Emcure to buy 7 brands
Sun Pharma and Ranbaxy have got approval from the Competition Commission for sale of seven brands to Emcure Pharma to comply with the fair trade watchdog's conditional nod for their USD 4-billion merger.
Mar 23, 2015, 20:08 PM IST
CAG blames I-T Dept for Rs 1348 cr tax loss in pharma sector
Coming down heavily on the I-T Department, CAG has said non-compliance of procedures for giving incentives to pharmaceutical firms, including Ranbaxy, Dr Reddy's and Piramal, resulted Rs 1,348.44 crore loss to the exchequer.
Mar 20, 2015, 19:28 PM IST
Ranbaxy loses approvals, exclusivity of 2 drugs in US
The DC Federal Court in the US has upheld the decision of the USFDA for rescinding tentative approvals given to it for generic digestive disorder drug Nexium and antiviral Valcyte.
Mar 03, 2015, 15:50 PM IST
Ranbaxy, Sun Pharma hit 52-week highs
Stocks of Ranbaxy climbed 3.46 percent to Rs 728 -- its one-year peak on the BSE.
Feb 02, 2015, 14:30 PM IST
Ranbaxy Q3 net loss widens to Rs 1,029.72 cr
The company had posted a net loss of Rs 158.94 crore during the October-December period of previous fiscal.
Jan 28, 2015, 15:47 PM IST
Ranbaxy forfeits 180 days exclusivity for stomach drugs
Drug major Ranbaxy on Tuesday said that the US health regulator has "determined" that the Indian drug manufacturer has forfeited its 180 days exclusivity for stomach and esophagus problems treatment tablets.
Jan 27, 2015, 13:16 PM IST
Sun Pharma chief expects Ranbaxy deal to be closed by mid-Feb
Drug major Sun Pharma's top executive Dilip S Shanghvi expects the USD 4-billion Ranbaxy deal to be concluded by middle of next month while stating that the key challenge before the combined entity would be to rebuild the confidence of health regulators.
Jan 25, 2015, 11:14 AM IST
Sun Pharma, Ranbaxy to sell 7 products to meet CCI conditions
While approving their USD 4-billion merger, Competition Commission of India (CCI) has asked the two companies to divest seven products to address anti-competitive concerns.
Dec 08, 2014, 20:26 PM IST
AstraZeneca-Ranbaxy drug settlement not anti-competitive
In a landmark judgement for pharma sector, a US jury has ruled that AstraZeneca's patent litigation settlement for blockbuster drug Nexium with Ranbaxy was not anti-competitive.
Dec 06, 2014, 22:57 PM IST
AstraZeneca, Ranbaxy prevail in Nexium antitrust trial
The US Federal Trade Commission estimates that pay-for-delay deals, in which a branded drugmaker pays a generic rival to stay off the market, cost consumers $3.5 billion each year.
Dec 06, 2014, 08:43 AM IST
German ban on Ranbaxy's Dewas product expands to entire EU
The company said it has discontinued manufacturing of an injectable antibiotic at its Dewas plant.
Dec 04, 2014, 19:35 PM IST
After US, Germany bans export of Ranbaxy's Dewas plant drugs
In fresh overseas troubles, drugmaker Ranbaxy has been barred from exporting certain antibiotics produced at its Dewas plant to Germany for non-compliance to 'good manufacturing practice' norms.
Dec 03, 2014, 21:18 PM IST
Sun-Ranbaxy deal gets FIPB nod
The Sun Pharma-Ranbaxy transaction would create the country's largest pharmaceutical company.
Dec 01, 2014, 18:39 PM IST
CCI decision on Sun-Ranbaxy deal before month end, says Chawla
This big ticket deal in the pharma space is also the first M&A transaction to have gone through public scrutiny amid concerns of adverse impact on fair competition in the market.
Nov 21, 2014, 21:37 PM IST
US court overturns bid by Ranbaxy to block launch of rival generic drugs
A US court has denied a request by drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc`s heartburn pill Nexium and Roche`s antiviral Valcyte.
Nov 20, 2014, 11:06 AM IST
Ranbaxy shares slump 5% mcap down Rs 1,072 crore
Shares of Ranbaxy Laboratories slumped nearly 5 percent today as the company sued USFDA over revoking an approval to sell generic versions of two drugs -- digestive disorder medicine Nexium and anti-viral Valcyte-- in the US market.
Nov 19, 2014, 17:26 PM IST
CCI to decide on Sun-Ranbaxy deal by month-end: Chawla
Competition Commission is likely to take the final decision in the USD 4 billion Sun Pharma-Ranbaxy deal by the end of this month, fair trade watchdog's chairman Ashok Chawla has said.
Nov 14, 2014, 15:17 PM IST
Ranbaxy loses 6 months exclusivity for generic antiviral drug
Drug firm Ranbaxy Laboratories today said the US health regulator has revoked its tentative approvals for its generic anti-viral drug and stomach and esophagus problems treatment tablets.
Nov 06, 2014, 20:12 PM IST
CCI to take final call on Sun Pharma-Ranbaxy deal this month
CCI is likely to finalse this month its decision on the USD 4 billion Sun Pharma-Ranbaxy deal -- the first M&A transaction to have gone through public scrutiny.
Nov 06, 2014, 15:36 PM IST
'Pharma cos may post robust top-line growth in Q2'
Russia/CIS and Japan growth is likely to be muted given the rouble/yen depreciation versus the Indian rupee.
Oct 12, 2014, 12:39 PM IST
